PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSugammadex
Bridion(sugammadex)
Bridion, Sugammadex (sugammadex) is an oligosaccharide pharmaceutical. Sugammadex was first approved as Bridion on 2008-07-25. It has been approved in Europe to treat neuromuscular blockade.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
anesthesia and analgesiaD000760
investigative techniquesD008919
Trade Name
FDA
EMA
Bridion, Sugammadex (discontinued: Sugammadex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sugammadex sodium
Tradename
Company
Number
Date
Products
BRIDIONMerck & CoN-022225 RX2015-12-15
2 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
bridionNew Drug Application2026-03-13
sugammadexANDA2026-09-23
sugammadex sodiumANDA2026-07-28
sugammadex sugammadexANDA2026-05-30
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
SUGAMMADEX SODIUM, BRIDION, MSD SUB MERCK
2024-06-25NPP
2024-01-22M-291
Patent Expiration
Patent
Expires
Flag
FDA Information
Sugammadex Sodium, Bridion, Msd Sub Merck
RE447332026-01-27DS, DPU-1794
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB35: Sugammadex
HCPCS
No data
Clinical
Clinical Trials
341 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuromuscular blockadeD019148——210164629101
General anesthesiaD000768———81231134
Delayed emergence from anesthesiaD055191——12—121833
AnesthesiaD000758———167720
Postoperative nausea and vomitingD020250EFO_0004888——113510
Postoperative painD010149—G89.18—2—237
Postoperative complicationsD011183—————336
Muscle relaxationD009126—————426
Renal insufficiencyD051437—N19112116
DiseaseD004194EFO_0000408R69———426
Show 92 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Morbid obesityD009767EFO_0001074——31—14
Stomach neoplasmsD013274EFO_0003897C16——1—12
Prostatic neoplasmsD011471—C61——1—12
Blood pressureD001794EFO_0004325——11——1
Anesthesia and analgesiaD000760———11——1
Heart rateD006339EFO_0004326——11——1
Beta-thalassemiaD017086Orphanet_848D56.1—11——1
ThalassemiaD013789EFO_1001996D56—11——1
HepatoblastomaD018197—C22.2—11——1
BurnsD002056—T30.0——1——1
Show 10 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hip osteoarthritisD015207EFO_1000786M16—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney diseasesD007674EFO_0003086N081———12
HypersensitivityD006967EFO_0003785T78.402————2
High-frequency jet ventilationD006611——1————1
AnaphylaxisD000707—T78.21————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bariatric surgeryD050110——————33
IntubationD007440——————33
Cardiac arrhythmiasD001145EFO_0004269I49.9————22
Thyroid diseasesD013959—E00-E07————22
Inhalation anesthesiaD000769——————22
Critical illnessD016638——————22
Colorectal neoplasmsD015179——————22
MyalgiaD063806—M79.1————22
Patient satisfactionD017060——————22
Airway extubationD060666——————22
Show 65 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSugammadex
INNsugammadex
Description
Sugammadex is an octasaccharide derivative that is gamma-cyclodextrin in which all eight primary hydroxy groups are replaced by 2-(carboxyethyl)sulfanyl groups. Used (as the octasodium salt) for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery. It has a role as a neuromuscular agent. It is an octasaccharide derivative and an organic sulfide. It is functionally related to a gamma-cyclodextrin. It is a conjugate acid of a sugammadex(8-).
Classification
Oligosaccharide
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
Identifiers
PDB—
CAS-ID343306-71-8
RxCUI—
ChEMBL IDCHEMBL2111107
ChEBI ID—
PubChem CID6918585
DrugBankDB06206
UNII ID361LPM2T56 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Bridion – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,980 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,547 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use